RxDoctor Payments Data

Carolyn Forbes, MD

Family Medicine · Tooele, UTNPI 1144251711

Payments from drug & device makers

$7,122in general payments, 2019–2025

Across 349 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$1K
  • Mylan Specialty L.p.$631
  • Lilly USA, LLC$448
  • Amgen$413
  • Boehringer Ingelheim$335
  • plus $3K from 40 others

What the payments were for

  • Travel & lodging$69010%
  • Food & beverage$6,43290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,122 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$245,830
Medicare patients
297
Services billed
5,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide92$111,122
EliquisApixaban65$82,138
FarxigaDapagliflozin Propanediol40$43,013
ProliaDenosumab23$40,118
JardianceEmpagliflozin27$35,508
OzempicSemaglutide18$31,805
XareltoRivaroxaban25$31,006
MyrbetriqMirabegron29$23,446
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$17,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,371
Febuxostat20$5,134
Trospium Chloride ErTrospium Chloride15$3,675
Omeprazole146$2,969
Atorvastatin Calcium248$2,649
Fluticasone Propionate91$2,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$448$111,12292 claims
PfizerEliquis$71$82,13865 claims
AstraZenecaFarxiga, Breztri Aerosphere$184$60,59756 claims
AmgenProlia$413$40,11823 claims
Boehringer IngelheimJardiance$335$35,50827 claims
Novo NordiskOzempic$328$31,80518 claims
Johnson & JohnsonXarelto$78$31,00625 claims
Astellas Pharma US IncMyrbetriq$242$23,44629 claims
GSKTrelegy Ellipta$267$14,37118 claims
AbbVieSynthroid$1,111$1,20321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Tooele

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →